Key result
Spot urinary sodium-guided stepwise diuretic escalation improves decongestion in acute heart failure.
Why the study?
Recent evidence needed to be synthesized on loop diuretic resistance during acute heart failure and on therapeutic approaches that improve sodium and fluid removal when standard loop diuretic treatment is inadequate.
Does stepwise, urinary sodium-guided decongestive therapy and sequential nephron blockade improve sodium and fluid removal in patients with acute heart failure and loop diuretic resistance?
Does stepwise, urinary sodium-guided decongestive therapy and sequential nephron blockade improve sodium and fluid removal in patients with acute heart failure and loop diuretic resistance?
Early spot urinary sodium monitoring combined with stepwise sequential nephron blockade (adding thiazides, acetazolamide, or SGLT2 inhibitors to intravenous loop diuretics) provides a practical, mechanism-based strategy to overcome loop diuretic resistance in acute heart failure.
Answers are grounded in this paper and cite their sources.
Urinary sodium-guided stepwise blockade may aid decongestion in diuretic-resistant AHF; supports consensus strategies but leaves open need for randomized confirmation.
Aim. This review aimed to synthesize recent evidence on loop diuretic resistance during acute heart failure (AHF) and to describe therapeutic approaches that improve sodium and fluid removal when standard loop diuretic treatment is inadequate. Materials and methods. A structured narrative review was performed with priority given to full-text and open-access publications from 2018 to 2026; earlier landmark primary and mechanistic studies were included when necessary. PubMed, PubMed Central, Google Scholar, ScienceDirect, SpringerLink and Oxford Academic were searched. Eligible sources included randomized trials, systematic reviews, meta-analyses, narrative syntheses, consensus publications and mechanistic investigations concerning AHF, loop diuretic treatment, urinary sodium, natriuretic response, sequential nephron blockade, ultrafiltration and biomarker-guided decongestion. Results. Loop diuretic resistance is a heterogeneous syndrome shaped by neurohormonal stimulation, reduced renal perfusion, altered drug handling, distal tubular sodium conservation, chronic kidney disease and cardiorenal syndrome. Early measurement of urinary sodium describes the natriuretic effect of therapy more directly than urine volume alone. Evidence supports stepwise management beginning with adequate intravenous loop diuretic exposure. If the response remains insufficient, escalation may include thiazide or thiazide-like add-on therapy, acetazolamide, SGLT2 inhibitors and selected adjunctive drugs. Ultrafiltration is reserved for refractory congestion, whereas sodium and fluid restriction should be individualized. Conclusions. Management should rely on early detection of inadequate sodium excretion, objective monitoring of renal response and individualized treatment selection. The most promising direction is mechanism-based decongestion that combines urine chemistry, renal function, electrolyte status and multimodal assessment of residual congestion.
No takes yet. Share an insight, caveat, or question.
Sokolova et al. (2026) conducted a review in Acute heart failure with loop diuretic resistance. Stepwise mechanism-based decongestive therapy (intravenous loop diuretic dose optimization, sequential nephron blockade with thiazides/acetazolamide/SGLT2 inhibitors, and ultrafiltration) vs. Standard loop diuretic therapy was evaluated on Natriuretic response and clinical decongestion (sodium and fluid removal). Stepwise management guided by early spot urinary sodium monitoring (<50-70 mmol/L) and sequential nephron blockade with thiazides, acetazolamide, or SGLT2 inhibitors improves decongestion in AHF.
Synapse has enriched 10 related papers. Consider them for comparative context: